DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation

Molecular and Cellular Biology

Volumn 25, Issue 12, 2005, Pages 5040-5051

  Mialon, Antoine ^a   Sankinen, Matti ^a   Söderström, Henrik ^a   Junttila, Teemu T ^a,b   Holmström, Tim ^a   Koivusalo, Riku ^b   Papageorgiou, Anastassios C ^a   Johnson, Randall S ^d   Hietanen, Sakari ^b,c   Elenius, Klaus ^a,b   Westermarck, Jukka ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TOPOTECAN; TRASTUZUMAB;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG MECHANISM; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REPORTER GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; GENE EXPRESSION REGULATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; TOPOTECAN;

EID: 20344400134     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.12.5040-5051.2005     Document Type: Article

References (41)

1. Basehoar, A. D., S. J. Zanton, and F. B. Pugh. 2004. Identification and distinct regulation of yeast TATA box-containing genes. Cell 116:699-709.
2. Blaney, S. M., D. E. Cole, F. M. Balis, K. Godwin, and D. G. Poplack. 1993. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in non-human primates. Cancer Res. 53:725-727.
3. Bost, F., R. McKaj, M. Bost, O. Potapova, N. M. Dean, and D. Mercola. 1999. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell. Biol. 19:1938-1949.
4. Brummelkamp, T. R., R. Bernards, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553.
5. Daoud, S. S., P. J. Munson, W. Reinhold, L. Young, V. V. Prabhu, Q. Yu, J. LaRose, K. W. Kohn, J. N. Weinstein, and Y. Pommier. 2003. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res. 63:2782-2793.
6. Darnell, J. E., Jr. 2002. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2:740-749.
7. Eferl, R., and E. F. Wagner. 2003. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3:859-868.
8. Fang, D., and T. K. Kerppola. 2004. Ubiquitin-mediated fluorescence complementation reveals that Jun ubiquitinated by Itch/AIP4 is localized to lysosomes. Proc. Natl. Acad. Sci. USA 101:14782-14787.
9. Fleischmann, G., G. Pflugfelder, E. K. Steiner, K. Javaherian, G. C. Howard, J. C. Wang, and S. C. Elgin. 1984. Drosophila DNA topoisomerase 1 is associated with transcriptionally active regions of the genome. Proc. Natl. Acad. Sci. USA 81:6958-6962.
10. Franklin, C. C., A. V. McCulloch, and A. S. Kraft. 1995. In vitro association between the Jun protein family and the general transcription factors, TBP and TFIIB. Biochem. J. 305:967-974.
11. Hayakawa, J., S. Mittal, Y. Wang, K. S. Korkmaz, E. Adamson, C. English, M. Omichi, M. McClelland, and D. Mercola. 2004. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol. Cell 16:521-535.
12. Huang, C. H., and J. Treat. 2001. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase 1 inhibitors. Oncology 61 (Suppl. 1):14-24.
13. Johnson, A. C., B. A. Murphy, C. M. Matelis, Y. Rubinstein, E. C. Piebenga, L. M. Akers, G. Neta, C. Vinson, and M. Birrer. 2000. Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression. Mol. Med. 6:17-27.
14. Johnson, R., B. Spiegelman, D. Hanahan, and R. Wisdom. 1996. Cellular transformation and malignancy induced by ras require c-Jun. Mol. Cell. Biol. 16:4504-4511.
15. Junttila, T. T., M. Laato, T. Vahlberg, K. O. Söderstrom, T. Visakorpi, J. Isola, and K. Elenius. 2003. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin. Cancer Res. 9:5346-5357.
16. Kafasla, P., M. Patrinou-Georgoula, J. D. Lewis, and A. Guialis. 2002. Association of the 72/74-kDa proteins, members of the heterogeneous nuclear ribonucleoprotein M group, with the pre-mRNA at early stages of spliceosome assembly. Biochem. J. 363:793-799.
17. Kim, J., S. Ahn, R. Guo, and Y. Daaka. 2003. Regulation of epidermal growth factor receptor internalization by G protein-coupled receptors. Biochemistry 42:2887-2894.
18. Kretzschmar, M., M. Meisterernst, and R. G. Roeder. 1993. Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc. Natl. Acad. Sci. USA 90:11508-11512.
19. Larsen, A. K., and C. Gobert. 1999. DNA topoisomerase I in oncology: Dr. Jekyll or Mr. Hyde? Pathol. Oncol. Res. 5:171-178.
20. Leppä, S., M. Eriksson, R. Saffrich, W. Ansorge, and D. Bohmann. 2001. Complex functions of AP-1 transcription factors in differentiation and survival of PC12 cells. Mol. Cell. Biol. 21:4369-4378.
21. Li, C. J., C. Wang, and A. B. Pardee. 1994. Camptothecin inhibits Tat-mediated transactivation of type 1 human immunodeficiency virus. J. Biol. Chem. 269:7051-7054.
22. Li, G., C. Gustafson-Brown, S. K. Hanks, K. Nason, J. M. Arbeit, K. Pogliano, R. M. Wisdom, and R. S. Johnson. 2003. c-Jun is essential for organization of the epidermal leading edge. Dev. Cell 4:865-877.
23. Li, T. K., and L. F. Liu. 2001. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 41:53-77.
24. Ljungman, M., and P. C. Hanawalt. 1996. The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Carcinogenesis 17:31-35.
25. Manning, A. M., and R. J. Davis. 2003. Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov. 2:554-565.
26. Mendelsohn, J. 2001. The epidermal growth factor receptor as a target for cancer therapy. Endocrinol. Relat. Cancer 8:3-9.
27. Merino, A., K. R. Madden, W. S. Lane, J. J. Champoux, and D. Reinberg. 1993. DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365:227-232.
28. Mondal, N., and J. D. Parvin. 2003. Transcription from the perspective of the DNA: twists and bumps in the road. Crit. Rev. Eukaryot. Gene Expr. 13:1-8.
29. Mondal, N., Y. Zhang, Z. Jonsson, S. K. Dhar, M. Kannapiran, and J. D. Parvin. 2003. Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity. Nucleic Acids Res. 31:5016-5024.
30. a.Nakajima, T., C. Uchida, S. F. Anderson, C. G. Lee, J. Hurwitz, J. D. Parvin, and M. Montminy. 1997. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90:1107-1112.
31. Paez, J. G., P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson, and M. Meyerson. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
32. Puig, O., F. Caspary, G. Rigaut, B. Rutz, E. Bouveret, E. Bragado-Nilsson, M. Wilm, and B. Seraphin. 2001. The tandem affinity purification (TAP) method: a general procedure of protein complex purification. Methods 24: 218-229.
33. Rallabhandi, P., K. Hashimoto, Y. Y. Mo, W. T. Beck, P. K. Moitra, and P. D'Arpa. 2002. Sumoylation of topoisomerase 1 is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin. J. Biol. Chem. 277:40020-40026.
34. Sabapathy, K., K. Hochedlinger, S. Y. Nam, A. Bauer, M. Karin, and E. F. Wagner. 2004. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell 15:713-725.
35. Sah, J. F., S. Balasubramanian, R. L. Eckert, and E. A. Rorke. 2004. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway: evidence for direct inhibition of ERK1/2 and AKT kinases. J. Biol. Chem. 279:12755-12762.
36. Shykind, B. M., J. Kim, L. Stewart, J. J. Champoux, and P. A. Sharp. 1997. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev. 11:397-407.
37. Treier, M., D. Bohmann, and M. Mlodzik. 1995. JUN cooperates with the ETS domain protein pointed to induce photoreceptor R7 fate in the Drosophila eye. Cell 83:753-760.
38. Vogt, P. K. 2001. Jun, the oncoprotein. Oncogene 20:2365-2377.
39. Westermarck, J., C. Weiss, J. Kast, R. Saffrich, A.-M. Musti, M. Wessely, W. Ansorge, B. Seraphin, M. Wilm, B. Valdez, and D. Bohmann. 2002. DexH/D RNA helicase RHII/Gu is a cofactor for c-Jun-activated transcription. EMBO J. 21:451-460.
40. Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:127-137.
41. Zenz, R., H. Scheuch, P. Martin, C. Frank, R. Eferl, L. Kenner, M. Sibilia, and E. F. Wagner. 2003. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev. Cell 4:879-889.